Product Description
Mechanisms of Action: Thrombin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Mucopolysaccharidosis VI *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Atrial Fibrillation|Venous Thromboembolism|Embolism and Thrombosis|Pulmonary Embolism|Venous Thrombosis|Mucopolysaccharidosis VI|Thromboembolism|Mucopolysaccharidosis
Phase 1: Atrial Fibrillation
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00437242 |
ITI103221 | P1 |
Terminated |
Atrial Fibrillation |
None |
2019-03-21 |
Treatments |
|
2017-002158-35 |
2017-002158-35 | P2 |
Completed |
Mucopolysaccharidosis |
2019-10-22 |
2022-03-13 |
Treatments |
|
NCT03370653 |
iMProveS | P2 |
Completed |
Mucopolysaccharidosis VI |
2019-09-24 |
31% |
2019-11-02 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
2005-001256-20 |
2005-001256-20 | P2 |
Completed |
Atrial Fibrillation |
2006-12-28 |
2022-03-12 |
Treatments |
|
NCT00240643 |
NCT00240643 | P2 |
Completed |
Atrial Fibrillation |
2006-12-01 |
2019-03-21 |
Treatments |
|
2004-000610-39 |
2004-000610-39 | P2 |
Completed |
Venous Thromboembolism |
2006-09-15 |
2022-03-12 |
Treatments |
|
NCT00244725 |
ITI101711 | P2 |
Completed |
Venous Thrombosis|Venous Thromboembolism|Embolism and Thrombosis|Pulmonary Embolism|Atrial Fibrillation |
2006-09-01 |
2019-03-21 |
Treatments |
|
NCT00041509 |
TEMPEST | P2 |
Completed |
Thromboembolism |
2003-05-01 |
2019-03-21 |
Treatments |